| 货号 | MAB2037-SP |
| 别名 | C5 |
| 反应种属 | Human |
| 应用 | Western Blot(1 µg/mL) ELISA Capture (Matched Antibody Pair)(2-8 µg/mL ) ELISA Detection (Matched Antibody Pair)(0.5-2.0 µg/mL ) ELISA Standard ( ) |
| 目标/特异性 | Detects human Complement Component C5/C5a in ELISAs and Western blots. In sandwich immunoassays, detects human Complement Component C5a by itself or in the context of Complement Component C5. In Western blots, this antibody does not cross-react with recombinant human Complement Component C2, recombinant mouse (rm) Complement Component C3d, or rmComplement Component C5a. |
| 使用方法 | Western Blot: 1 µg/mL ELISA Capture (Matched Antibody Pair): 2-8 µg/mL ELISA Detection (Matched Antibody Pair): 0.5-2.0 µg/mL ELISA Standard : Neutralization: Measured by its ability to neutralize Complement Component C5a-induced N-acetyl-beta -D-glucosaminidase release in the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line. Klos, A. et al. (1992) Biochemistry 31:11274. The Neutralization Dose (ND50) is typically 0.04-0.12 µg/mL in the presence of 10 ng/mL Recombinant Human Complement Component C5a and cytochalasin‑B. |
| 来源 | Monoclonal Mouse IgG1 Clone # 295003 |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 727 (Human); 15139 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Attenuation of Staphylococcus aureus-Induced Bacteremia by Human Mini-Antibodies Targeting the Complement Inhibitory Protein Efb. | |
| 纯化方式 | Protein A or G purified from hybridoma culture supernatant |
| 免疫原 | E. coli-derived recombinant human Complement Component C5a Thr678-Arg751 Accession # P01031 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
| 背景 | Human complement component C5a (C5a) is an enzymatically generated glycoprotein that belongs to a family of structurally and functionally related proteins known as anaphylatoxins. C5a is a 74 amino acid (aa) peptide that is created by the activity of C5a convertase on the C5 alpha -chain (1, 2). Human C5a has four alpha -helices plus three intrachain disulfide bonds that create a triple loop structure (3). In serum, proteolytic processing removes the C-terminal arginine, creating a low activity C5a desArg74 molecule (1). Human C5a is 60% and 54% aa identical to mouse and rat C5a, respectively. C5a binds to a signaling G-protein coupled receptor (C5aR/CD88) and a non-signaling GPCR termed C5L2 (4). Activation of Cd88 results in neutrophil chemotaxis and endothelial cell activation (1, 5). It also triggers an oxidative burst in macrophages and neutrophils, and induces release of histamine in basophils and mast cells. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
N-Acetyl-beta -D-Glucosaminidase Release Induced by Complement Component C5a and Neutralization by Human Complement Component C5a Antibody. Recombinant Human Complement Component C5a (Catalog # 2037-C5) induces N‑acetyl‑ beta ‑D‑glucosaminidase release in the the dibutyryl cyclic-AMP differentiated U937 human histiocytic lymphoma cell line in a dose-dependent manner (orange line). N-Acetyl-beta -D-Glucosaminidase Release elicited by Recombinant Human Complement Component C5a (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Complement Component C5a Monoclonal Antibody (Catalog # MAB2037). The ND50 is typically 0.04‑0.12 µg/mL in the presence of cytochalasin‑B. |
